AnaptysBio (ANAB) Earning Positive News Coverage, Report Shows

Headlines about AnaptysBio (NASDAQ:ANAB) have been trending positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AnaptysBio earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.5481550503191 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news stories that may have effected Accern’s analysis:

A number of brokerages recently commented on ANAB. SunTrust Banks, Inc. began coverage on AnaptysBio in a report on Wednesday. They set a “buy” rating and a $115.00 target price for the company. Wedbush restated a “positive” rating and set a $82.00 target price (up from $75.00) on shares of AnaptysBio in a report on Tuesday, November 7th. Zacks Investment Research upgraded AnaptysBio from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a report on Tuesday, August 22nd. Jefferies Group LLC began coverage on AnaptysBio in a report on Thursday, November 9th. They set a “buy” rating and a $101.00 target price for the company. Finally, Stifel Nicolaus restated a “buy” rating and set a $35.00 target price on shares of AnaptysBio in a report on Tuesday, September 12th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $84.78.

AnaptysBio (NASDAQ ANAB) traded up $2.97 during mid-day trading on Friday, reaching $74.86. The company’s stock had a trading volume of 507,000 shares, compared to its average volume of 205,320. The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $78.98.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. equities analysts forecast that AnaptysBio will post -1.72 EPS for the current fiscal year.

In other AnaptysBio news, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the sale, the insider now owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

ILLEGAL ACTIVITY NOTICE: “AnaptysBio (ANAB) Earning Positive News Coverage, Report Shows” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply